Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) shares dropped 4.6% on Wednesday . The stock traded as low as $3.50 and last traded at $3.51, with a volume of 178,747 shares. The stock had previously closed at $3.68.

DRNA has been the topic of several research reports. Leerink Swann reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Thursday, June 30th. Jefferies Group reaffirmed a “buy” rating and issued a $19.00 target price on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 10th. Chardan Capital dropped their target price on Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating on the stock in a research report on Monday, August 8th. Stifel Nicolaus decreased their price target on Dicerna Pharmaceuticals from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Tuesday, May 10th. Finally, Cowen and Company reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Sunday, June 26th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $11.85.

The stock has a 50 day moving average of $3.38 and a 200-day moving average of $4.23. The company’s market capitalization is $70.56 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.09. Analysts expect that Dicerna Pharmaceuticals Inc. will post ($3.17) earnings per share for the current year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.